Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845707 | 0.86 | HRH3 (0.46) | PTGS2HRH3MAPTMAPK1HTR1A | |
| SCHEMBL12845325 | 0.86 | HRH3 (0.46) | PTGS2HRH3MAPTMAPK1HTR1A | |
| SCHEMBL12554173 | 0.86 | HRH3 (0.46) | PTGS2HRH3MAPTMAPK1HTR1A | |
| SCHEMBL15267551 | 0.86 | HTT (0.41) | PTGS2LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL15267542 | 0.85 | EGFR (0.33) | PTGS2 | |
| SCHEMBL12810915 | 0.84 | EGFR (0.33) | USP2ALOX15MEN1KMT2A | |
| SCHEMBL8075495 | 0.82 | HTR2A (0.36) | PTGS2MAPTSMN1; SMN2HTR1APTGS1 | |
| SCHEMBL13130737 | 0.82 | HTR2A (0.36) | PTGS2MAPTSMN1; SMN2HTR1APTGS1 | |
| SCHEMBL19114061 | 0.82 | BCHE (0.32) | PTGS2 | |
| SCHEMBL12845423 | 0.81 | HRH3 (0.46) | PTGS2HRH3MAPK1SMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393801-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| US-8541442-B2 | Indole derivatives as anticancer agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | Janssen Pharmaceutica NV a corporation | 2011-12-01 | — | — | US | disclosed |
| WO-2010089327-A2 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294846-A1 | INDOLE DERIVATIVES AS ANTICANCER AGENTS | IDO1, IDO2, INMT | PTGS2 686/4885HRH3 2218/4885LMNA 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.